Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018

OBJECTIVES: Cost-effectiveness analysis can guide decision making about health interventions, but the appropriate cost-effectiveness threshold to use is unclear in most countries. The World Health Organization (WHO) recommends vaccinating girls 9 to 14 years against human papillomavirus (HPV), but o...

Descripción completa

Detalles Bibliográficos
Autor principal: Jit, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Themed Section: Vaccines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813214/
https://www.ncbi.nlm.nih.gov/pubmed/33431154
http://dx.doi.org/10.1016/j.jval.2020.07.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813214/
https://www.ncbi.nlm.nih.gov/pubmed/33431154
http://dx.doi.org/10.1016/j.jval.2020.07.012

Ejemplares similares